(2024). Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach. Diabetologia. http://doi.org/10.1007/s00125-024-06190-9
. A. Hattersley
First name
A.
Middle name
T.
Last name
Hattersley
(2023). Comparison of causal forest and regression-based approaches to evaluate treatment effect heterogeneity: an application for type 2 diabetes precision medicine. Bmc Med Inform Decis Mak, 23, 110. http://doi.org/10.1186/s12911-023-02207-2
. (2022). Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study. Lancet Digit Health, 4, e873-e883. http://doi.org/10.1016/s2589-7500(22)00174-1
. (2016). Adherence to Oral Glucose-Lowering Therapies and Associations With 1-Year HbA1c: A Retrospective Cohort Analysis in a Large Primary Care Database. Diabetes Care. http://doi.org/10.2337/dc15-1194
. (2017). Cohort profile for the MASTERMIND study: using the Clinical Practice Research Datalink (CPRD) to investigate stratification of response to treatment in patients with type 2 diabetes. BMJ Open. http://doi.org/10.1136/bmjopen-2017-017989
. (2018). Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. Diabetes Care. http://doi.org/10.2337/dc18-0344
. (2018). Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017. Diabetes Obes Metab. http://doi.org/10.1111/dom.13346
. (2018). Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. Diabetes Care. http://doi.org/10.2337/dc17-1827
. (2019). Time trends in prescribing of type 2 diabetes drugs, glycemic response and risk factors: a retrospective analysis of primary care data, 2010-2017. Diabetes Obes Metab. http://doi.org/10.1111/dom.13687
. (2019). What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study. BMC Med. http://doi.org/10.1186/s12916-019-1307-8
.